Vivani Medical Inc. Total Liabilities
Vivani Medical Inc. total liabilities. Based on the latest financial reports, Vivani Medical Inc. (VANI) has total liabilities worth $22.67 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check VANI asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Vivani Medical Inc. (2012–2025)
Total liabilities of Vivani Medical Inc. from 2012 to 2025. This chart illustrates how Vivani Medical Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Vivani Medical Inc. Competitors by Total Liabilities
The table below lists competitors of Vivani Medical Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mr. Blue Corporation
KQ:207760
|
Korea | ₩29.39 Billion |
|
5E Advanced Materials Inc
NASDAQ:FEAM
|
USA | $3.89 Million |
|
Bien Yapi Urunleri Sanayi Turizm ve Ticaret A.S.
IS:BIENY
|
Turkey | TL14.36 Billion |
|
Dekuple
PA:DKUPL
|
France | €204.20 Million |
|
Tanami Gold NL
AU:TAM
|
Australia | AU$5.12 Million |
|
Hites S.A.
SN:HITES
|
Chile | CL$299.48 Billion |
|
Fulin Plastic Industry Cayman Holding Co Ltd
TW:1341
|
Taiwan | NT$1.01 Billion |
|
Fluent Inc
NASDAQ:FLNT
|
USA | $67.03 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Vivani Medical Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Vivani Medical Inc..
Liquidity & Leverage Metrics
Vivani Medical Inc. Total Liabilities Ratios Explained
Vivani Medical Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vivani Medical Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vivani Medical Inc. (2012–2025)
The table below shows the annual total liabilities of Vivani Medical Inc. from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $23.66 Million | -1.20% |
| 2024-12-31 | $23.95 Million | -4.33% |
| 2023-12-31 | $25.04 Million | +266.99% |
| 2022-12-31 | $6.82 Million | +128.31% |
| 2021-12-31 | $2.99 Million | -8.54% |
| 2020-12-31 | $3.27 Million | -64.96% |
| 2019-12-31 | $9.32 Million | +22.72% |
| 2018-12-31 | $7.60 Million | +14.86% |
| 2017-12-31 | $6.62 Million | +16.83% |
| 2016-12-31 | $5.66 Million | -29.07% |
| 2015-12-31 | $7.98 Million | -5.55% |
| 2014-12-31 | $8.45 Million | -61.40% |
| 2013-12-31 | $21.89 Million | +98.38% |
| 2012-12-31 | $11.04 Million | -- |
About Vivani Medical Inc.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the t… Read more